prestige biopharm hd201

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

Hyundai Motor Co. said on Tuesday that it released the 2025 Santa Fe, a model year change of its flagship midsize sports utility vehicle (SUV) The A...

SAN DIEGO, California -- South Korea’s SK Biopharmaceuticals Co. is considering acquiring firms in the US, or the sales rights to some of thei...

Celltrion Inc. and SK Biopharmaceuticals Co. are witnessing improving sales revenue and profitability by selling their products through their own ma...

South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...

South Korea's SK Biopharmaceuticals Co. announced on Thursday that it has signed a contract with Dong-A ST to transfer the rights to commercialize t...

SK Biopharmaceuticals Co. is gearing up to explore the European market for its flagship epilepsy drug Cenobamate, while looking for new mergers and ...

Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, is expanding its CDMO b...

South Korea's SK Biopharmaceuticals announced on Friday a strategic tie-up with Hikma MENA FZE, marking the introduction of its new epilepsy medicat...

South Korea’s SK Biopharmaceuticals Co. is aiming to triple its enterprise value to $15 billion by 2026 with the goal of rising to the top run...

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, announced on Tuesday that it will partici...

South Korea’s SK Biopharmaceuticals Co. has obtained the sales approval for its antiepileptic treatment Cenobamate in Canada, paving the way f...

Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter I...

Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistam...

Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Tuesday th...

On Wednesday, SK Biopharmaceuticals Co. announced that its US subsidiary, SK Life Sciences Inc., held a "National Sales Meeting" in San Diego. The p...

Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer...

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US,  has applied to the Australian clini...

Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. ...

SK Group's new drug development subsidiary SK Biopharmaceuticals Co. will begin clinical trials for a wearable device that can detect and predict ep...

South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...

South Korean SK Biopharmaceuticals' epilepsy treatment Cenobamate has seen rapid growth on the US market.The company on Thursday said the medic...

South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil&rsquo...

South Korean SK Biopharmaceuticals Co. launched its epilepsy treatment Cenobamate in the UK, rapidly expanding the company’s presence in Europ...

South Korea's top travel and accommodation platform Yanolja Inc., backed by SoftBank, was on Thursday named as the preferred buyer of a majority sta...

South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...

South Korea's SK Holdings Co. has offloaded an 11% stake in SK Biopharmaceuticals Co. in a block trade for 1.1 trillion won ($1 billion) as part of ...

South Korea's benchmark Kospi reached a two-year high closing at 2485.87 points on Nov. 11, posting an eight-session winning streak driven by imminent...

Big Hit Entertainment Co. Ltd., the label behind the K-pop boy band BTS and SK Biopharmaceuticals Co. Ltd. are moving ahead with their planned initial...